Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 38, 2008 - Issue 5
Submit an article Journal homepage
69
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Comparative evaluation of absorption, distribution, and excretion of YM758, a novel If channel inhibitor, between albino and non-albino rats

K.-I. Umehara Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan
,
K. Seya ADME/TOX Research Institute, Sekisui Medical Co., Ltd, Ibaraki, Japan
,
T. Sonoda Astellas Research Technologies Co., Ltd, Tokyo, Japan
,
E. Nakamura Astellas Research Technologies Co., Ltd, Tokyo, Japan
,
K. Noguchi Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan
,
T. Usui Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan
&
H. Kamimura Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan
 show all
Pages 527-539 | Received 03 Feb 2008, Accepted 18 Feb 2008, Published online: 22 Sep 2008

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

K.-I. Umehara, K. Seya, T. Iwatsubo, K. Noguchi, T. Usui & H. Kamimura. (2008) Tissue distribution of YM758, a novel If channel inhibitor, in pregnant and lactating rats. Xenobiotica 38:10, pages 1274-1288.
Read now
K.-I. Umehara, T. Iwatsubo, K. Noguchi, T. Usui & H. Kamimura. (2008) Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3 and implications for drug–drug interactions. Xenobiotica 38:9, pages 1203-1218.
Read now

Articles from other publishers (7)

Naoyuki Nakada. (2016) Investigation of Metabolite Profile of YM758, a Novel If Channel Inhibitor. Drugs in R&D 16:2, pages 205-216.
Crossref
Ken-ichi Umehara, Naoyuki Nakada, Kiyoshi Noguchi, Takafumi Iwatsubo, Takashi Usui & Hidetaka Kamimura. (2009) Investigation of Long-Term Retention of Unchanged (−)- N -{2-[( R )-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide, A Novel “Funny” If Current Channel Inhibitor, and Its Metabolites in the Eyeball and Thoracic Aorta of Rats . Drug Metabolism and Disposition 37:11, pages 2137-2144.
Crossref
. (2009) Current World Literature. Current Opinion in Ophthalmology 20:5, pages 417-422.
Crossref
Ken-ichi Umehara, Nobuaki Shirai, Takafumi Iwatsubo, Kiyoshi Noguchi, Takashi Usui & Hidetaka Kamimura. (2009) Identification of Human Metabolites of (–)- N -{2-[( R )-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, and Investigation of the Transporter-Mediated Renal and Hepatic Excretion of These Metabolites . Drug Metabolism and Disposition 37:8, pages 1646-1657.
Crossref
Ken-ichi Umehara, Kouichi Wada, Kiyoshi Noguchi, Takafumi Iwatsubo, Takashi Usui & Hidetaka Kamimura. (2009) Relationship between Exposure of (–)- N -{2-[( R )-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a “Funny” If Current Channel Inhibitor, and Heart Rate Reduction in Tachycardia-Induced Beagle Dogs . Drug Metabolism and Disposition 37:7, pages 1427-1433.
Crossref
K-I. Umehara, Y. Susaki, R. H. J. van Teylingen, J. N. Neat, F. Ndikum-moffor, K. Noguchi, T. Usui, A. Parkinson & H. Kamimura. (2008) Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. European Journal of Drug Metabolism and Pharmacokinetics 33:4, pages 211-223.
Crossref
K-I. Umehara, T. Nakamata, K. Suzuki, K. Noguchi, T. Usui & H. Kamimura. (2008) Pharmacokinetics of YK754, a novel If channel inhibitor in rats, dogs and humans. European Journal of Drug Metabolism and Pharmacokinetics 33:2, pages 117-127.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.